Investment Thesis
ProKidney is a pre-revenue stage biotech with negative stockholders equity of -$1.0B, indicating technical insolvency despite strong cash position. While revenue growth of +1075% YoY is impressive, the $226K absolute revenue against $44.9M operating losses and -$45.5M free cash flow reveals unsustainable unit economics and an ~2.3-year cash runway at current burn rates.
Strengths
- Exceptional revenue growth trajectory (+1075% YoY from biotech development stage
- Strong absolute cash position of $101.9M providing near-term operational runway
- Excellent liquidity ratios (9.06x current/quick) and low debt burden
Risks
- Negative stockholders equity of -$1.0B represents fundamental balance sheet insolvency
- Operating cash burn of -$41.7M annually with current revenue of only $226K is not sustainable
- No visible path to profitability; operating margins at -19,881% indicate R&D-heavy pre-commercial stage with execution risk
Key Metrics to Watch
- Quarterly revenue trends and absolute revenue inflection toward sustainability
- Operating cash burn rate and timeline to cash flow breakeven
- Stockholders equity trajectory and recapitalization events or major funding rounds
Financial Metrics
Revenue
226.0K
Net Income
-20.0M
EPS (Diluted)
$-0.23
Free Cash Flow
-45.5M
Total Assets
292.8M
Cash
101.9M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-19,881.9%
Net Margin
-8,865.9%
ROE
N/A
ROA
-6.8%
FCF Margin
-20,119.0%
Balance Sheet & Liquidity
Current Ratio
9.06x
Quick Ratio
9.06x
Debt/Equity
N/A
Debt/Assets
10.1%
Interest Coverage
-2,995.53x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-16T07:36:33.650635 |
Data as of: 2026-03-31 |
Powered by Claude AI